ANTIBODIES TO BENZO[A]PYRENE, ESTRADIOL AND PROGESTERONE AND GENE POLYMORPHISMS OF CYTOKINES: ASSOCIATIONS WITH LUNG CANCER IN MEN

Previous studies have revealed associations of antibodies, specific to chemical carcinogens and steroid hormones with lung cancer in men. However, the mechanisms of their formation and action were remained unclear. In particular, the relationships between antibodies and gene polymorphisms of cytokines were un- known. The purpose of this study was to identify possible associations between occurrence of A class antibodies, specific to benzo[a]pyrene, estradiol and progesterone (IgA-Bp, IgA-Es and IgA-Pg), and frequency of genetic polymorphisms of IL1RN VNTR, IL1В (rs1143634, rs16944), IL4 VNTR, IL6 (rs1800795), IL10 (rs1800896), TNFA (rs1800629, rs361525) genes in healthy male smokers and lung cancer patients.

We have examined 381 men with non-small cell lung cancer and 158 apparently healthy donors without respiratory diseases. A non-competitive solid phase immunoassay of antibodies was performed. Analysis of polymorphic loci of IL1RN (VNTR, intron 2), IL4 (VNTR, intron 3) was performed by means of conventional PCR; IL1В (rs1143634, rs16944), IL6 (rs1800795) SNPs were detected by RFLP, and IL10 (rs1800896), TNFA (rs1800629, rs361525) genotyping was carried out with TaqMan Real-time PCR. Results of the study have shown that the proportion of cases with high level of IgA-Pg and low levels of both IgA-Bp and IgA-Es among the lung cancer patients was lower than in healthy men (OR = 0.31, p < 0.0001). Vice versa, the ratio of cases with high levels of both IgA-Bp and IgA-Es and low levels of IgA-Pg was higher in lung cancer patients (OR = 3.6, p < 0.0001). No relationships were revealed between the levels of antibodies, and rates of genetic polymorphisms for the studied cytokines in both groups of men. At the same time, the detected associations of IgA-Bp, IgA-Es and IgA-Pg with lung cancer proved to be significant only in carriers of certain cytokine genotypes, e.g., in AG IL10 heterozygotes (OR = 5.1, p < 0.0001).

In conclusion, these results provide indirect evidence that IgA-Bp and IgA-Es could stimulate initiation and promotion of lung carcinogenesis. On the contrary, IgA-Pg could inhibit the promotion of carcinogenesis. Immunoassay of these antibodies combined with molecular biology studies of IL10 gene variants are recommended for the lung cancer risk assessment.

1. Белогубова Е.В., Того А.В., Суворова И.К., Карпова М.Б., Улыбина Ю.М., Зайцева О.А., Яцук О.С., Шуткин В.А., Рябоконь С.А., Соколенко А.П., Иевлева А.Г., Чекмарева Е.В., Лемехов В.Г., Колосков А.В., Кучинский А.П., Хансон К.П., Имянитов Е.Н. Распределение аллелей гена CYP1A1 у больных раком легкого, доноров среднего возраста и пожилых людей без онкологической патологии // Вопросы онкологии, 2004. Т. 50, № 2. С. 165-168. [Belogubova Е.V., Togo A.V., Suvorova I.K., Karpova M.B., Ulybina Yu.M., Zaitseva O.A., Jatsook O.S., Shootkin V.A., Ryabokon S.A., Sokolenko A.P., Iyevleva A.G., Chekmareva E.V., Lemekhov V.G., Koloskov A.V., Kuchinsky A.P., Hanson K.P., Imyanitov E.H. CYP1A1 allele distribution in lung cancer patients, middleaged donor and elderly tumor-free subjects. Voprosy onkologii = Problems of Oncology, 2004, Vol. 50, no. 2, pp. 165- 168. (In Russ.)]

2. Глушков А.Н., Поленок Е.Г., Аносова Т.П., Савченко Я.А., Баканова М.Л., Минина В.И., Мун С.А., Ларин С.А., Костянко М.В. Сывороточные антитела к бензо[a]пирену и хромосомные аберрации в лимфоцитах периферической крови у рабочих углеперерабатывающего предприятия // Российский иммунологический журнал, 2011. Т. 5 (14), № 1. С. 39-44. [Glushkov A.N., Polenok E.G., Anosova T.P., Savchenko Ya.A., Bakanova M.L., Minina V.I., Mun S.A., Larin S.A., Kostyanko M.V. Serum antibodies to benzo[a]pyrene and chromosomal aberrations in lymphocytes peripheral blood at the workers of coal processing enterprise. Rossijskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2011, Vol. 5(14), no. 1, pp. 39-44. (In Russ.)].

3. Глушков А.Н. Клиническая иммунохимия канцерогенеза: новые задачи и перспективы // Российский иммунологический журнал, 2013. Т. 7 (16), № 1. С. 27-34. [Glushkov A.N. Immunochemistry on carcinogenesis: new tasks and perspectives. Rossijskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2013, Vol. 7 (16), no. 1, pp. 27-34. (In Russ.)]

4. Глушков А.Н., Поленок Е.Г., Костянко М.В., Титов В.А., Вафин И.А., Рагожина С.Е. Взаимное влияние антител к бензо[a]пирену, эстрадиолу и прогестерону на риски возникновения рака легкого // Российский иммунологический журнал, 2015. Т. 9 (18), № 3. С. 343-349. [Glushkov A.N., Polenok E.G., Kostyanko M.V., Titov V.A., Vafin I.A., Ragozhina S.E. Mutual effects of antibodies to benzo[a]pyrene, estradiol and progesterone on the lung cancer risks. Rossijskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2015, Vol. 9 (18), no. 3, pp. 343-349. (In Russ.)]

5. Гордеева Л.А., Глушкова О.А., Воронина Е.Н., Шаталина И.В., Шутров А.Е., Попова О.С., Гареева Ю.В., Симонова Т.А., Сутулина И.М., Филипенко М.Л., Глушков А.Н. Ассоциации материнских полиморфизмов генов цитокинов (IL-1B, IL-1RN, TNF, IL-4, IL-6) с врожденными пороками развития у плода и новорожденного // Иммунология, 2013. Т. 34, № 6. С. 298-304. [Gordeeva L.A., Glushkova O.A., Voronina E.N., Shatalina I.V., Shutrov A.E., Popova O.S., Gareeva Yu.V., Simonova T.A., Sutulina I.M., Filipenko M.L., Glushkov A.N. Association of maternal polymorphisms of cytokine gene (IL1B, IL1RN, TNF, IL4, IL6) with congenital malformations in fetus and newborn. Immunologia = Immunology, 2013, Vol. 34, no. 6, pp. 298-304. (In Russ.)]

6. Давыдов М.И., Богуш Т.А., Полоцкий Б.Е., Тюляндин С.А. Эстрогеновые рецепторы β – новая мишень в терапии немелкоклеточного рака легкого // Вестник РАМН, 2012. Т. 67, № 2. С. 16-22. [Davidov M.I., Bogush T.A., Polotskiy B.E., Tylyandin S.A. Estrogen receptors β – new target in cellular lung cancer treatment. Vestnik Rossiyskoi akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences, 2012, Vol. 67, no. 2, pp. 16-22. (In Russ.)]

7. Худолей В.В. Канцерогены: характеристики, закономерности, механизмы действия. СПб.: НИИ Химии СПбГУ, 1990. 419 с. [Khudoley V.V. Carcinogens: characteristics, patterns, mechanisms of action]. St.-Peterburg: Research Institute of Chemistry, St. Petersburg State University, 1990. 419 p.

8. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev., 2000, Vol. 9, no. 1, pp. 3-28.

9. Borska L., Andrys C., Krejsek J., Palicka V., Chmelarova M., Hamakova K., Kremlacek J., Borsky P., Fiala Z. Serum level of antibody against benzo[a]pyrene – 7,8-diol-9,10-epoxide-DNA adducts in people dermally exposed to PAHs. J. Immunol. Res., 2014, Vol. 2014, Article ID 834389, 6 p. doi: 10.1155/2014/834389.

10. Bourtourault M., Shacoori V., Guerin J., Saiag B., Rault B. Effects of simultaneous active immunization against 17 beta-estradiol and testosterone on pituitary and ovarian activity in rat. Res. Commun. Chem. Pathol. Pharmacol., 1991, Vol. 72, no. 3, pp. 273-284.

11. Černohorská H., Klimešová S., Lepša L., Jinoch P., Milcová A., Schmuczerová J., Topinka J., Lábaj J. Influence of immunization with non-genotoxic PAH-KLH conjugates on the resistance of organisms exposed to benzo[a]pyrene. Mut. Res., 2012, Vol. 742, no. 1-2, pp. 2-10.

12. Chagnaud J.L., Faiderbe S., Geffard M. Identification and immunochemical characterization of IgA in sera of patients with mammary tumors. Int. J. Cancer, 1992, Vol. 50, pp. 395-401.

13. Chang C.F., Roberts A.J., Reeves J.J. Increased luteinizing hormone secretion and ovarian function in Heifers actively immunized against estrogen and progesterone. J. Anim. Sci., 1987, Vol. 65, no. 3, pp. 771-776.

14. Chen Z., Zhang Y., Yang J., Jin M., Wang X.W., Shen Z.Q., Qiu Z., Zhao G., Wang J., Li J.W. Estrogen promotes benzo[a]pyrene-induced lung carcinogenesis through oxidative stress damage and cytochrome c-mediated caspase-3 activation pathway in female mice. Cancer. Lett., 2011, Vol. 308, no. 1, pp. 14-22.

15. Curtis G.L., Ryan W.L., Stenbäck F. Antibody stimulation of benzo[a]pyrene carcinogenesis. Cancer Lett., 1978, Vol. 4, no. 4, pp. 223-228.

16. De Buck S.S., Augustijns P., Muller C.P. Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J. Pharmacol. Experim. Therap., 2005, Vol. 313, no. 2, pp. 640-646.

17. Fucic A., Gamulin M., Ferencic Z., Rokotov D.S., Katic A., Bartonova A., Lovasic I.B., Merlo D.F. Lung cancer and environmental exposure: a review of our current state of knowledge with reference to the role of hormones and hormone receptors as an increased risk factor for developing lung cancer in man. Toxicol. Pathol., 2010, Vol. 38, no. 6, pp. 849-855.

18. Glushkov A.N. Immunological disbalance in carcinogenesis. Med. Hypotheses, 2014, Vol. 83, no. 2, pp. 166-171.

19. Glushkov A.N., Polenok E.G., Ustinov V.A. Immunomodulation of human carcinogenesis by the blood serum antibodies against benzo[a]pyrene, estradiol and progesterone. Open J. Immunol., 2016, Vol. 6, no. 3, pp. 67-72.

20. Grova N., Prodhomme E.J., Schellenberger M.T., Farinelle S., Muller C.P. Modulation of carcinogen bioavailability by immunization with benzo[a]pyrene – conjugate vaccines. Vaccine, 2009, Vol. 27, no. 31, pp. 4142-4151.

21. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J. Intern. Med., 2013, Vol. 4, no. 2, pp. 627-635.

22. Hillier S.G., Groom G.V., Boyns A.R., Cameron E.H. Effects of active immunisation against steroids upon circulating hormone concentrations. J. Steroid Biochem., 1975, Vol. 6, no. 3-4, pp. 529-535.

23. Hirose T., Morito K., Kizu R., Toriba A., Hayakawa K., Ogawa S., Inoue S., Muramatsu M., Masamune Y. Estrogenic/antiestrogenic activities of benzo[a]pyrene monohydroxy derivatives. J. Health Sci., 2001, Vol. 47, no. 6, pp. 552-558.

24. Ishibashi H., Suzuki T., Suzuki S., Niikawa H., Lu L., Miki Y., Moriya T., Hayashi S., Handa M., Kondo T., Sasano H. Progesterone receptor in non-small cell lung cancer – a potent prognostic factor and possible target for endocrine therapy. Cancer Res., 2005, Vol. 65, no. 14, pp. 6450-6458.

25. Kreuzer M., Gerken M., Heinrich J., Kreienbrock L., Wichmann H.E. Hormonal factors and risk of lung cancer among women? Int. J. Epidemiol., 2003, Vol. 32, no. 2, pp. 263-271.

26. Liu K., Lin X., Zhou Q., Ma T., Han L., Mao G., Chen J., Yue X., Wang H., Zhang L., Jin G., Jiang J., Zhao J., Zou B. The associations between two vital GSTs genetic polymorphisms and lung cancer risk in the Chinese population: evidence from 71 studies. PLoS ONE, 2014, Vol. 9, no. 7, e102372. doi: 10.1371/journal.pone.0102372.

27. Lodovici M., Luceri C., Guglielmi F., Bacci C., Akpan V., Fonnesu M.L., Boddi V., Dolara P. Benzo(a)pyrene diolepoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidemiol. Biomarkers Prev., 2004, Vol. 13, no. 8, pp. 1342-1348.

28. Nagata Y., Hanagiri T., Mizukami M., Kuroda K., Shigematsu Y., Baba T., Ichiki Y., Yasuda M., So T., Takenoyama M., Sugio K., Nagashima A., Yasumoto K. Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer, 2009, Vol. 65, no. 1, pp. 91-97.

29. Newman M.J., Light B.A., Weston A., Tollurud D., Clark J.L., Mann D.L., Blackmon J.P., Harris C.C. Defection and characterization of human serum antibodies to polycyclic aromatic hydrocarbon diol-epoxide DNA adducts. J. Clin. Invest., 1988, Vol. 82, no. 1, pp. 145-153.

30. Ozbek N., Birinci A., Karaoglanoglu O., Coban A.Y., Okumus B., Cakir S., Durupinar B. HLA alleles and lung cancer in a Turkish population. Ann Saudi Med., 2004, Vol. 24, no. 2, pp. 106-111.

31. Pauk N., Klimesova S., Kara J., Topinka J., Labaj J. The relevance of monitoring of antibodies against polycyclic aromatic hydrocarbon (PAH) and PAH-DNA adducts in serum in relation to lung cancer and chronic obstructive pulmonary disease (COPD). Neoplasma, 2013, Vol. 60, no. 2, pp. 182-187.

32. Pavannello S., Fedeli U., Mastrangelo G., Rota F., Overvad K., Raaschou-Nielsen O., Tjønneland A., Vogel U. Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study. Cancer Genet., 2012, Vol. 205, no. 6, pp. 278-284.

33. Peng W.J., He Q., Yang J.X., Wang B.X., Lu M.M., Wang S., Wang J. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol. Biol. Rep., 2012, Vol. 39, no. 5, pp. 5187-5194.

34. Perera F.P., Tang D., Brandt-Rauf P., Santella R.M., Mooney L.V., Tu Y.H., Bendkowska I., Bell D.A. Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and protein CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians’ health study. Cancer Epidemiol. Biomarkers Prev., 2006, Vol. 15, no. 7, pp. 1417-1419.

35. Petruzzelli S., Celi A., Pulera N., Baliva F., Viegi G., Carrozzi L., Ciacchini G., Bottai M., Di Pede F., Paoletti P., Giuntini C. Serum antibodies to benzo(a) pyrene diol epoxide DNA adducts in the general population: effects of air pollution, tobacco smoking and family history of lung diseases. Cancer Res., 1998, Vol. 58, no. 8, pp. 4122-4126.

36. Pouns O., Mangas A., Coveňas R., Geffard M. Circulating antibodies directed against “polycyclic aromatic hydrocarbon-like” structures in sera of cancer patients. Cancer Epidemiol., 2009, Vol. 33, no. 1, pp. 3-8.

37. Rengarajan T., Rajendran P., Nandakumar N., Lokeshkumar B., Rajendran P., Nishigaki I. Exposure to polycyclic aromatic hydrocarbons with special focus on cancer. Asian Pac. J. Trop. Biomed., 2015, Vol. 5, no. 3, pp. 182-189.

38. Schellenberger M.T., Farinelle S., Williéme S., Muller C.P. Evolution of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. Hum. Vaccin., 2011, Vol. 7, no. 1, pp. 166-173.

39. Silbart L.K., Rasmussen M.V., Oliver A.R. Immunoprophylactic intervention in chemical toxicity and carcinogenicity. Vet. Hum. Toxicol., 1997, Vol. 39, no. 1, pp. 37-43.

40. Stabile L.P., Dacic S., Land S.R., Lenzner D.E., Dhir R., Acquafondata M., Landreneau R.J., Grandis J.R., Siegfried J.M. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin. Cancer Res., 2011, Vol. 17, no. 1, pp. 154-164.

41. Xu J., Yin Z., Cao S., Gao W., Liu L., Yin Y., Liu P., Shu Y. Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS ONE, 2013, Vol. 8, no. 5, e63654. doi: 10.1371/ journal.pone.0063654.

42. Zhang Y., Liu C., Peng H., Zhang J., Feng Q. IL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: a literature review and meta-analysis. PLoS ONE, 2012, Vol. 7, no. 9, e46017. doi: 10.1371/journal.pone.0046017.

43. Zhao J., Wang H., Hu W., Jin Y. Effect of HLA-B-associated transcript 3 polymorphisms on lung cancer risk: a meta-analysis. Med. Sci. Monit., 2014, Vol. 20, pp. 2461-2465.

44. Zhou W., Zhang S., Hu Y., Na J.,Wang N., Ma X., Yuan L., Meng F. Retraction note to: Meta-analysis of the associations between TNF-α or IL-6 gene polymorphisms and susceptibility to lung cancer. Eur. J. Med. Res., 2016, Vol. 21, no. 1, p. 31.